Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Deal Gives Synosis A Leg Up In Central Nervous System Space

This article was originally published in The Pink Sheet Daily

Executive Summary

The newly launched company will develop five discontinued Roche central nervous system drug candidates.

You may also be interested in...



Roche Global Head Of Pharma Partnering Dan Zabrowski: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Swiss firm’s R&D alliances comprise more than 80 deals in 20 countries.

Roche Global Head Of Pharma Partnering Dan Zabrowski: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Swiss firm’s R&D alliances comprise more than 80 deals in 20 countries.

Synosia Licenses Rufinamide From Novartis In Anxiety, Bipolar Indications

The sodium channel blocker could have advantages over selective serotonin reuptake inhibitors, CEO tells “The Pink Sheet” DAILY.

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel